A lab supplier trying to stop the slide
- Avantor is a pick-and-shovel supplier for labs and biopharma plants, with VWR as its main distribution brand.
- The new Avantor Revival plan splits the company into VWR Distribution and Services and Bioscience and Medtech Products.
- VWR Distribution organic revenue fell 5% in Q1 2026, which management says should be the bottom.
- Bioscience and Medtech Products organic revenue fell 2% in Q1, but orders were stronger, with book-to-bill above 1.1x.
- The main test is whether Avantor can return to positive organic growth in the second half of 2026 while margins are under pressure.
A turnaround with early green shoots
Avantor is in a reset year. New leadership has reorganized the company around two clearer jobs: sell through the VWR channel, and sell higher-margin made-by-Avantor products through any channel. That is the heart of the Avantor Revival plan.
The bull case is simple. VWR's online store upgrades are starting to lift traffic and conversion, meaning more visitors turn into buyers. Bioscience and Medtech Products also showed better demand in Q1 2026, with book-to-bill above 1.1x. That means orders were higher than sales for the quarter. If those orders ship on time, revenue can improve in the back half of 2026.
The bear case is that the slide is not over. VWR Distribution organic revenue fell 5% in Q1 2026, and Bioscience and Medtech Products organic revenue fell 2%. Management says VWR bottomed in Q1 and BMP should bottom in Q2, but investors still need proof. Finn's overall view stays cautious because growth, margins, and execution are all being repaired at the same time.
The next big markers are clear: positive organic revenue growth in the second half of 2026, proof that the BMP order book becomes revenue, and better adjusted operating margin progression despite a $10 million to $20 million operating income headwind tied to Middle East-driven inflation.
VWR channel, Avantor-made products
Avantor makes money by supplying the things labs and biopharma factories need every day. That includes consumables, equipment, chemicals, services, fluid handling products, and specialty materials. Some products are made by Avantor. Others are sold through its distribution network.
The VWR Distribution and Services segment is the larger channel business. It sells many brands, provides on-site and equipment services, and includes controlled environment consumables. This business can be steady when customers keep ordering lab supplies, but it is exposed to price pressure and market share loss.
Bioscience and Medtech Products is the higher-margin product business. It includes J.T.Baker process chemicals, Masterflex fluid handling, NuSil silicones, and proprietary lab chemicals. This side can earn better margins, but it also depends on manufacturing reliability and on-time delivery.
The model breaks if the company cannot fix its own execution. Management has called out self-inflicted problems such as too much complexity, too much central control, and weak frontline decision-making. The Revival plan is meant to fix that, but 2026 is still a transition year.
What Avantor sells
VWR distribution
VWR is the main channel for lab consumables, equipment, and instruments. It is large, but Q1 2026 organic revenue fell 5%, so the near-term job is to stop share loss.
Services
Avantor provides on-site and equipment services for customers that need lab operations to keep running. These services help tie customers to the VWR channel.
J.T.Baker process chemicals
J.T.Baker chemicals are used in bioprocessing and other controlled workflows. Management highlighted double-digit process chemicals growth as a positive sign.
Masterflex fluid handling
Masterflex products move fluids through lab and production systems. This fits the higher-margin Bioscience and Medtech Products segment.
NuSil specialty silicones
NuSil makes specialty silicones used in medical and other technical applications. It gives Avantor exposure to medtech demand.
Controlled environment consumables
These products are used in clean and controlled settings, such as biopharma production. They now sit inside VWR Distribution and Services under the new reporting structure.
Two pieces after the reset
The segment mix is based on 2025 revenue under the Q1 2026 resegmentation. VWR Distribution and Services is much larger, while Bioscience and Medtech Products carried the higher 2025 adjusted operating margin.
What could still break
VWR share loss becomes permanent
High impact · Medium oddsVWR Distribution and Services is about 72% of 2025 revenue, so weak performance here matters a lot. Management believes the 5% Q1 2026 organic revenue decline was the bottom. If customers have moved to rivals for good, the Revival plan may not be enough.
BMP orders do not turn into shipments
High impact · Medium oddsBioscience and Medtech Products had book-to-bill above 1.1x in Q1 2026, which points to solid demand. The risk is execution. Prior bottlenecks in manufacturing and supply chain hurt throughput and on-time delivery.
Margins stay lower for longer
High impact · Medium oddsAvantor guided for 100 to 150 basis points of EBITDA margin contraction in 2026. The causes include mix, incentive compensation reset, and investments tied to the Revival plan. If revenue does not recover, those investments could leave the company with lower profit power.
Goodwill cushion disappears
Medium impact · Medium oddsAvantor recorded a $785 million goodwill impairment in Q3 2025 tied to the Distribution reporting unit. As of Q1 2026, the VWR Distribution reporting unit's estimated fair value exceeded its carrying value by only 5.5%. A weaker forecast or higher discount rate could trigger another impairment.
Inflation costs grow
Medium impact · Medium oddsManagement estimated a $10 million to $20 million 2026 operating income headwind from Middle East-driven inflation. Freight and raw material costs could rise more than expected. That would make the margin recovery harder.
In one breath
What does Avantor do?
Avantor supplies labs and biopharma manufacturers with consumables, chemicals, equipment, services, and specialty materials. Its VWR brand is the main distribution channel.
Why is Avantor in a turnaround?
Management says the company became too complex and too centralized. The Avantor Revival plan is meant to simplify the business, improve accountability, and fix commercial and supply chain execution.
What is book-to-bill, and why does it matter for Avantor?
Book-to-bill compares new orders with sales shipped in the period. A figure above 1.0 means orders were higher than sales, so BMP's above 1.1x Q1 2026 reading suggests demand is better than reported revenue showed.
What should investors watch next?
The key test is whether Avantor returns to positive organic revenue growth in the second half of 2026. Investors should also watch BMP shipment conversion, VWR share trends, and segment margin improvement.